Skip NavigationSkip to Content

NCI at Frederick Scientific Publications Advanced Search

Search

  1. NCI-F Publications

  2. Return to Quick Search
Search
  2. Year Published:

Your search returned 50 results.
User Information
Export Records
  1. 1.   Englerin A Inhibits EWS-FLI1 DNA Binding in Ewing Sarcoma Cells
  2. Caropreso, V.; Darvishi, E.; Turbyville, T. J.; Ratnayake, R.; Grohar, P. J.; McMahon, J. B.; Woldemichael, G. M.
  3. The Journal of biological chemistry. 2016, 6-May; 291(19): 10058-66.
  1. 2.   Configuration-dependent Presentation of Multivalent IL-15:IL-15Ralpha Enhances the Antigen-specific T Cell Response and Anti-tumor Immunity
  2. Hong, E.; Usiskin, I. M.; Bergamaschi, C.; Hanlon, D. J.; Edelson, R. L.; Justesen, S.; Pavlakis, G. N.; Flavell, R. A.; Fahmy, T. M.
  3. The Journal of biological chemistry. 2016, 22-Apr; 291(17): 8931-50.
  1. 3.   The Proteasome Ubiquitin Receptor hRpn13 and Its Interacting Deubiquitinating Enzyme Uch37 Are Required for Proper Cell Cycle Progression
  2. Randles, L.; Anchoori, R. K.; Roden, R. B.; Walters, K. J.
  3. The Journal of biological chemistry. 2016, 15-Apr; 291(16): 8773-83.
  1. 4.   High-throughput single-molecule screen for small-molecule perturbation of splicing and transcription kinetics
  2. Day, C. R.; Chen, H.; Coulon, A.; Meier, J. L.; Larson, D. R.
  3. Methods (San Diego, Calif.). 2016, 1-Mar; 96: 59-68.
  1. 5.   Plumbagin, a naphthaquinone derivative induces apoptosis in BRCA 1/2 defective castrate resistant prostate cancer cells as well as prostate cancer stem-like cells
  2. Reshma, R. S.; Sreelatha, K. H.; Somasundaram, V.; Satheesh Kumar, S.; Nadhan, R.; Nair, R. S.; Srinivas, P.
  3. Pharmacological Research. 2016, Mar; 105: 134-45.
  1. 6.   Design, synthesis, and biological evaluation of water-soluble amino acid prodrug conjugates derived from combretastatin, dihydronaphthalene, and benzosuberene-based parent vascular disrupting agents
  2. Devkota, L.; Lin, C. M.; Strecker, T. E.; Wang, Y.; Tidmore, J. K.; Chen, Z.; Guddneppanavar, R.; Jelinek, C. J.; Lopez, R.; Liu, L.; Hamel, E.; Mason, R. P.; Chaplin, D. J.; Trawick, M. L.; Pinney, K. G.
  3. Bioorganic & Medicinal Chemistry. 2016, 1-Mar; 24(5): 938-56.
  1. 7.   Interactions between breast cancer susceptibility loci and menopausal hormone therapy in relationship to breast cancer in the Breast and Prostate Cancer Cohort Consortium
  2. Gaudet, M. M.; Barrdahl, M.; Lindstrom, S.; Travis, R. C.; Auer, P. L.; Buring, J. E.; Chanock, S. J.; Eliassen, A. H.; Gapstur, S. M.; Giles, G. G.; Gunter, M.; Haiman, C.; Hunter, D. J.; Joshi, A. D.; Kaaks, R.; Khaw, K. T.; Lee, I. M.; Le March, L.; Milne, R. L.; Peeters, P. H.; Sund, M.; Tamimi, R.; Trichopoulou, A.; Weiderpass, E.; Yang, X. R.; Prentice, R. L.; Feigelson, H. S.; Canzian, F.; Kraft, P.
  3. Breast Cancer Research and Treatment. 2016, Feb; 155(3): 531-40.
  1. 8.   TrkA in vivo function is negatively regulated by ubiquitination
  2. Kiris, E.; Wang, T.; Yanpallewar, S.; Dorsey, S. G.; Becker, J.; Bavari, S.; Palko, M. E.; Coppola, V.; Tessarollo, L.
  3. Journal of Neuroscience. 2014, 12-Mar; 34(11): 4090-8.
  1. 9.   The importance of Raf dimerization in cell signaling
  2. Freeman, A. K.; Ritt, D. A.; Morrison, D. K.
  3. Small GTPases. 2013, Jul-Sep; 4(3): 180-5.
  1. 10.   TNF-alpha: an activator of CD4+FoxP3+TNFR2+ regulatory T cells
  2. Chen, X.; Oppenheim, J. J.
  3. Current directions in autoimmunity. 2010 11: 119-34.
  1. 11.   Potential for therapeutic targeting of tumor stem cells
  2. Saini, V.; Shoemaker, R. H.
  3. Cancer Science. 2010, Jan; 101(1): 16-21.
  1. 12.   Targeting prostate cancer stem cells
  2. Crea, F.; Mathews, L. A.; Farrar, W. L.; Hurt, E. M.
  3. Anti-cancer agents in medicinal chemistry. 2009, Dec; 9(10): 1105-13.
  1. 13.   Virus maturation as a new HIV-1 therapeutic target
  2. Adamson, C. S.; Salzwedel, K.; Freed, E. O.
  3. Expert opinion on therapeutic targets. 2009, Aug; 13(8): 895-908.
  1. 14.   Cytotoxic and HIF-1alpha inhibitory compounds from Crossosoma bigelovii
  2. Klausmeyer, P.; Zhou, Q.; Scudiero, D. A.; Uranchimeg, B.; Melillo, G.; Cardellina, J. H.; Shoemaker, R. H.; Chang, C. J.; McCloud, T. G.
  3. Journal of Natural Products. 2009, May 22; 72(5): 805-12.
  1. 15.   Anti-HIV-1 therapeutics: from FDA-approved drugs to hypothetical future targets
  2. Adamson, C. S.; Freed, E. O.
  3. Molecular Interventions. 2009, Apr; 9(2): 70-4.
  1. 16.   Inhibitors of the NF-kappaB activation pathway from Cryptocarya rugulosa
  2. Meragelman, T. L.; Scudiero, D. A.; Davis, R. E.; Staudt, L. M.; McCloud, T. G.; Cardellina, J. H. 2nd.; Shoemaker, R. H.
  3. Journal of Natural Products. 2009, Mar 27; 72(3): 336-9.
  1. 17.   Short and sweet: evolution of a small glycopeptide from a bladder disorder to an anticancer lead
  2. Barchi, J. J., Jr.; Kaczmarek, P.
  3. Molecular Interventions. 2009, Feb; 9(1): 14-7.
  1. 18.   Synthesis of conformationally locked carbocyclic nucleoside phosphonates to probe the active site of HIV-1 RT
  2. Saneyoshi, H.; Vu, B. C.; Hughes, S. H.; Boyer, P. L.; Sarafianos, S. G.; Marquez, V. E.
  3. Nucleic acids symposium series (2004). 2008 (52): 623-4.
  1. 19.   The synthetic peptide WKYMVm attenuates the function of the chemokine receptors CCR5 and CXCR4 through activation of formyl peptide receptor-like 1
  2. Li, B. Q.; Wetzel, M. A.; Mikovits, J. A.; Henderson, E. E.; Rogers, T. J.; Gong, W.; Le, Y.; Ruscetti, F. W.; Wang, J. M.
  3. Blood. 2001 97(10): 2941-2947.
  1. 20.   Presence of potential nickel-responsive element(s) in the mouse MTH1 promoter
  2. Liang, R.; Igarashi, H.; Tsuzuki, T.; Nakabeppu, Y.; Sekiguchi, M.; Kasprzak, K. S.; Shiao, Y. H.
  3. Annals of Clinical and Laboratory Science. 2001 31(1): 91-98.
  1. 21.   Possible roles of nitric oxide and redox cell signaling in metal-induced toxicity and carcinogenesis: a review
  2. Buzard, G. S.; Kasprzak, K. S.
  3. Journal of Environmental Pathology, Toxicology and Oncology. 2000 19(3): 179-99.
  1. 22.   HIV-Inhibitory prenylated xanthones and flavones from Maclura tinctoria
  2. Groweiss, A.; Cardellina, J. H.; Boyd, M. R.
  3. Journal of Natural Products. 2000 63(11): 1537-1539.
  1. 23.   N36, a synthetic N-terminal heptad repeat domain of the HIV-1 envelope protein gp41, is an activator of human phagocytes
  2. Le, Y. Y.; Jiang, S.; Hu, J. Y.; Gong, W. H.; Su, S. B.; Dunlop, N. M.; Shen, W. P.; Li, B. Q.; Wang, J. M.
  3. Clinical Immunology. 2000 96(3): 236-242.
  1. 24.   Structural and biochemical mechanisms of HIV-1 RT drug resistance
  2. Boyer, P. L.; Gao, H. Q.; Serafianos, S.; Ding, J.; Clark, P.; Clark, A.; Arnold, E.; Hughes, S. H.
  3. Conference on Retroviruses and Opportunistic Infections. 1999, 218 (abstract no. S33).
  1. 25.   HIV-1 induced in the setting of IL-2 therapy is transient and not derived from PBMC proviral reservoirs
  2. Imamichi, H.; Zhang, Y. M.; Kovacs, J.; Dewar, R.; Metcalf, J.; Vogel, S.; Salzman, N.; Lane, H. C.
  3. Conference on Retroviruses and Opportunistic Infections. 1999, 135 (abstract no. 358).
NCI at Frederick

You are leaving a government website.

This external link provides additional information that is consistent with the intended purpose of this site. The government cannot attest to the accuracy of a non-federal site.

Linking to a non-federal site does not constitute an endorsement by this institution or any of its employees of the sponsors or the information and products presented on the site. You will be subject to the destination site's privacy policy when you follow the link.

ContinueCancel